Mundipharma introduces Remsima (infliximab) in six European countries
To be launched in Germany, Italy, the UK, Netherlands, Belgium and Luxembourg, Remsima is authorised for the treatment of patients with Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.